These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22639052)

  • 1. Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.
    Zakrzewski D; Seferynska I; Warzocha K; Hryniewiecki T
    Int J Hematol; 2012 Jul; 96(1):132-5. PubMed ID: 22639052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
    Orlandi EM; Rocca B; Pazzano AS; Ghio S
    Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
    [No Abstract]   [Full Text] [Related]  

  • 4. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 5. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
    Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
    Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 9. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
    Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute respiratory failure from nilotinib-associated diffuse alveolar hemorrhage.
    Donatelli C; Chongnarungsin D; Ashton R
    Leuk Lymphoma; 2014 Oct; 55(10):2408-9. PubMed ID: 24467220
    [No Abstract]   [Full Text] [Related]  

  • 12. Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib.
    Caocci G; Maioli MA; Atzeni S; Piras R; Carboni N; La Nasa G
    Leuk Res; 2012 Sep; 36(9):e206-8. PubMed ID: 22742815
    [No Abstract]   [Full Text] [Related]  

  • 13. [Peripheral artery occlusive disease of the lower limbs: Rapid aggravation in a patient taking nilotinib for chronic myeloid leukemia].
    Gautier V; Mirault T; Azarine A; Alsac JM; Sapoval M; Réa D; Messas E
    J Mal Vasc; 2015 Jul; 40(4):231-9. PubMed ID: 26139550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
    Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
    Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 16. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia.
    Tokatlı M; Ismayilov R; Erkin Çınar O; Haznedaroğlu İC
    Turk J Haematol; 2024 Mar; 41(1):59-60. PubMed ID: 38153228
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Jarkowski A; Sweeney RP
    Pharmacotherapy; 2008 Nov; 28(11):1374-82. PubMed ID: 18956997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
    Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
    Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.